The Britain Government said it is close to a $ 624 million supply deal with Sanofi and Glaxosmithkline for 60 million doses of a potential COVID-19 vaccine.
Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than pre
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
Olufikayo Owoeye
Olufikayo is a graduate of Computer Science with Economics from the prestigious Obafemi Awolowo University Ile-Ife. Prior to joining BusinessDay, he has worked with some notable media outfit in the country. Armed with training in Consulting and Investment banking from Edubridge Academy. He has a very keen interest in Emerging markets, Politics, Mergers and Acquisition. He loves traveling and watching football. You can contact him via [email protected]
